Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. This phase I study determined the safety, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the intravenously administered, highly selective EZH2 inhibitor, GSK2816126, (NCT02082977). Doses of GSK28161...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-12, Vol.25 (24), p.7331-7339
Hauptverfasser:	Yap, Timothy A, Winter, Jane N, Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P, Ribrag, Vincent, McCabe, Michael T, Creasy, Caretha L, Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein - metabolism Female Humans Indoles - administration & dosage Indoles - adverse effects Indoles - pharmacokinetics Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - metabolism Lymphoma, B-Cell - pathology Male Maximum Tolerated Dose Middle Aged Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology Patient Safety Prognosis Pyridones - administration & dosage Pyridones - adverse effects Pyridones - pharmacokinetics Tissue Distribution Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!